

Natamycin treatment outcome in keratomycosis patients

Sukrit Pershad¹, Subhav Pershad², Nagababu Pyadala^{3*}

¹Postgraduate, Department of Ophthalmology, MNR Medical College and Hospital, Sangareddy, Telangana State, INDIA.

²Postgraduate, Department of Ophthalmology, Sarojini Devi Eye Hospital, Hyderabad, Telangana State, INDIA.

³Research Associate, MNR Foundation for research and innovation, Sangareddy, Telangana State, INDIA.

Email: nagababu00799@gmail.com

Abstract

In this study, 50 fungal isolates from 50 patients with fungal keratitis were tested *in vitro* for their susceptibility to natamycin and the mean minimum inhibitory concentrations of natamycin (MICn) were correlated with clinical outcome. The mean MICn for various groups of fungi from patients with either early (<10 days) or late (≥10 days) presentation was correlated with the outcome. *Aspergillus flavus* showed resistance to natamycin with a high mean MICn (21 µg/ml). While the clinical response in all patients with early *A. flavus* keratitis was good it was poor in late cases. *Fusarium* species, *Acremonium* species were sensitive with low mean MICn (*Fusarium*: 7-9 µg/ml, *Acremonium*: 5-8 µg/ml). We conclude that despite susceptibility of most fungal species causing keratitis to natamycin, the treatment outcome is poor in advanced fungal keratitis.

Key Words: Keratomycosis, minimum inhibitory concentration, natamycin, susceptibility, treatment outcome.

*Address for Correspondence:

Dr. Nagababu Pyadala, MNR Foundation for research and innovation, Sangareddy, Telangana State, INDIA.

Email: nagababu00799@gmail.com

Received Date: 02/01/2018 Revised Date: 31/01/2018 Accepted Date: 12/02/2018

DOI: <https://doi.org/10.26611/1009526>

Access this article online

Quick Response Code:



Website:

www.medpulse.in

Accessed Date:
18 February 2018

information is lacking in keratomycosis. Only a limited number of antifungal susceptibility testing of ocular isolates has been reported and except for one none have correlated with response to treatment in the patients^{5,6}. Therefore in the present study fungal isolates from keratitis patients were tested *in vitro* for their susceptibility to natamycin eye drop and the mean minimum inhibitory concentrations (MIC) were correlated with the clinical outcome with topical 5% natamycin eye drops.

INTRODUCTION

Keratomycosis is the leading cause of ocular ulceration worldwide and fungi are the most common etiological agent causing corneal infections¹⁻³. Polyenes, triazoles, and echinocandins are the antifungal drugs commonly used for treatment of fungal keratitis¹⁻³. Among these antifungal drugs, natamycin is the mainly used for the treatment of corneal ulcer worldwide. Although there are antifungal drugs, but treatment outcome is poor in fungal keratitis as compared to bacterial infections¹⁻³. In the non-ophthalmic literature a fairly wide range of antifungal susceptibility test results are available for prediction of clinical outcome in fungal infections⁴. In contrast, such

MATERIALS AND METHODS

In this prospective, interventional study corneal scrapings from 50 patients with microbial keratitis were processed and interpreted as per standard protocol³. Consent was obtained from all patients. Taking appropriate laboratory precautions all significant fungal growth were tested for their susceptibility to natamycin eye drop (Sun pharmaceutical Ind. Ltd, Mumbai, India) by the previously described microbroth dilution method⁷. All patients received intensive treatment with one hourly 5% natamycin eye drops in the affected eye for the first three days with subsequent modification as per response. 20 patients were given oral ketoconazole (200 mg twice

daily) and 5 patients received oral fluconazole (150 mg twice daily). Clinical outcome at one month was considered for analysis. An ulcer was defined either completely healed or resolving (reduction in infiltrate size) or worsened (increase in infiltrate size, keratoplasty). Since the treatment outcome is known to be affected by severity of disease the mean MIC of natamycin for different groups of fungi for patients presenting within 10 days (early onset) or after 10 days (late onset) of symptoms were correlated with the clinical outcome⁸.

RESULTS

Fungal species wise comparison of mean MIC of natamycin with treatment outcome was made among the

patients with early and late onset disease [Table 1]. *A. flavus* (n = 14) showed the highest mean MIC (early-15 µg/ml, late-21 µg/ml) suggesting lowest susceptibility to natamycin. Excluding the patients lost to follow up 2 out of 5 patients had poor clinical response in the late group (*A. flavus*) while 1 had worsened in the early group (*A. flavus*). *A. fumigatus*, in contrast, showed high susceptibility to natamycin *in vitro* with mean MIC of 2 µg/ml. MIC of natamycin was relatively low for *Fusarium* species with mean MIC between 7- 14 µg/ml. Among the dematiaceous fungi, *Curvularia* species were isolated in 3 patients and natamycin showed low MIC against these isolates (mean MIC in early - 1.4 µg/ml, late - 4 µg/ml).

Table 1: Treatment outcome of patients with early (<10 days) and late (>10 days) onset of fungal keratitis caused by various groups of fungi and their correlation with MIC of natamycin.

| Fungal isolates | Treatment outcome | Total No. (%) | Mean MIC (µg/ml) | Healed | Resolving | Worsened | No follow up |
|-----------------------|-------------------|---------------|------------------|--------|-----------|----------|--------------|
| Aspergillus fumigatus | Early | 18 | 2 | 4 | 3 | 1 | 1 |
| | Late | 4 | 4 | 1 | 1 | 0 | 0 |
| Aspergillus flavus | Early | 18 | 15 | 4 | 3 | 1 | 1 |
| | Late | 10 | 21 | 2 | 1 | 2 | 0 |
| Aspergillus terreus | Late | 4 | 17 | 1 | 1 | 0 | 0 |
| Aspergillus niger | Early | 2 | 2 | 1 | 0 | 0 | 0 |
| Curvularia spp | Early | 4 | 1.4 | 1 | 0 | 1 | 0 |
| | Late | 2 | 4 | 0 | 1 | 0 | 0 |
| Fusarium spp | Early | 18 | 7 | 3 | 4 | 1 | 1 |
| | Late | 6 | 9 | 1 | 1 | 0 | 1 |
| Acremonium spp | Early | 8 | 5 | 2 | 1 | 0 | 1 |
| | Late | 4 | 8 | 1 | 0 | 1 | 0 |

DISCUSSION

A notable publication by Prajna *et al*, has convincingly shown that eye drop preparations are an alternative to pharmaceutical grade natamycin (not available to most laboratories) for testing antifungal susceptibility⁷. This study applied the same technique to evaluate the MIC of natamycin against various isolates of fungi from corneal scrapings of patients with mycotic keratitis. Owing to a small sample size in various groups of fungi, the mean MIC was considered for comparison rather than MIC₉₀ or MIC₅₀⁹. Susceptibility breakpoints for natamycin have not been described so far in CLSI guidelines, however, MIC of 16 µg/ml or less is considered to indicate susceptibility of a fungal isolate⁷. This study reassuringly found low MIC of natamycin (≤16 µg/ml) in all fungal isolates tested except *A. flavus*. *A. flavus* associated with keratitis is a particularly virulent fungus and is known to be associated with poor outcome in keratomycosis⁸. Apart from the toxins, its perilous status is compounded by its resistance to natamycin. It is not known whether this resistance is inherent to this species¹⁰. All isolates of *Fusarium* species were sensitive to natamycin but that

did not translate to good clinical outcome in patients with *Fusarium* keratitis irrespective of early or late presentation. This probably points to the well known fact of poor penetration of natamycin especially in presence of advanced fungal keratitis affecting deeper layers of the cornea. Most encouraging results were obtained with respect to dematiaceous fungi [Table 1]. This study shows that a low MIC of natamycin (susceptible fungi) was not always associated with good treatment outcome with natamycin in fungal keratitis. As is well known, a large number of factors affect success or failure of medical therapy of fungal keratitis, severity of infection being one of them^{8,11,12}. Our treatment protocol for fungal keratitis includes systemic antifungals for patients with the ulcer more than 6 mm in diameter or extending beyond anterior half of the stroma or when there is hypopyon. Systemic antifungal therapy given in some of the patients in this study may be a confounding factor which was not analyzed and is one of the limitations of this study. Using logistic regression Shapiro *et al.*, showed that a two fold increase in MIC results in 47% reduction in the odds of healing⁶. However, results of the present study suggest

that such a conclusion may be too simplistic and a considerably large study addressing multiple factors would be necessary to determine the effect of various parameters on the treatment outcome of fungal keratitis. Despite the limitation of small sample size in each group of fungi and statistically non significant results, we believe that our results are clinically significant. The susceptibility of *A. flavus* to natamycin is particularly poor and patients with this infection may require aggressive treatment, closer follow up and early surgical intervention. *In vitro* susceptibility of most other species of fungi, such as *Fusarium* spp., *A. fumigatus*, *Acremonium* spp., *Curvularia* spp. etc., to natamycin may account for good clinical response when the intervention occurs early in the disease.

REFERENCES

1. Srinivasan M. Fungal keratitis. *Curr Opin Ophthalmol.* 2004; 15:321–7.
2. Thomas PA. Current perspective in ophthalmic mycosis. *Clin Microbiol Rev.* 2003; 16:730–97.
3. Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: Experience of over a decade. *Indian J Ophthalmol.* 2009; 57:273–9.
4. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? *Clin Infect Dis.* 2002; 35:982–9.
5. Gopinathan U, Garg P, Fernandes M, Sharma S, Sreedharan A, Rao GN. The epidemiological features and laboratory results of fungal keratitis: A 10-year review at a referral eye care center in south India. *Cornea.* 2002; 21:555–9.
6. Shapiro BL, Lalitha P, Loh AR, Fothergill AW, Prajna NV, Srinivasan M, et al. Susceptibility testing and clinical outcome in fungal keratitis. *Br J Ophthalmol.* 2010; 94:383–4.
7. Lalitha P, Vijaykumar R, Prajna NV, Fothergill AW. In vitro natamycin susceptibility of ocular isolates of *Fusarium* and *Aspergillus* species: Comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. *J Clin Microbiol.* 2008; 46:3477–8.
8. Lalitha P, Prajna NV, Kabra A, Mahadevan K, Srinivasan M. Risk factors for treatment outcome in fungal keratitis. *Ophthalmology.* 2006; 113:526–30.
9. Tavanti A, Hensgens LA, Mogavero S, Majoros L, Senesi S, Campa M. Genotypic and phenotypic properties of *Candida parapsilosis sensu strictu* strains isolated from different geographic regions and body sites. *BMC Microbiol.* 2010; 10:203.
10. Leema G, Kaliyamurthy J, Geraldine P, Thomas PA. Keratitis due to *Aspergillus flavus*: Clinical profile, molecular identification of fungal strains and detection of aflatoxin production. *Mol Vis.* 2010; 16:843–54.
11. Vemuganti GK, Garg P, Gopinathan U, Naduvilath TJ, John RK, Rajeev B, et al. Evaluation of agent and host factors in progression of mycotic keratitis: A histological and microbiological study of 167 buttons. *Ophthalmology.* 2002; 109:1538–46.
12. Florcruz NV, Peczon I, Jr. Medical interventions for fungal keratitis. *Cochrane Database Syst Rev.* 2008:CD004241.

Source of Support: None Declared
Conflict of Interest: None Declared